BioSeek Initiates Systems Biology Compound Evaluation Collaboration with UCB
News Dec 06, 2007
BioSeek, Inc. has that it has entered into a collaboration agreement with UCB, a global biopharmaceutical leader based in Belgium. Under the collaboration, BioSeek will apply its BioMAP® Systems to evaluate a number of UCB compounds across several target classes, in support of target differentiation, lead development, and drug candidate selection activities at UCB.
"We are excited to be working closely with UCB, an innovative biopharmaceutical company combining distinctive strengths in chemistry and biology, and focusing on severe diseases in three important therapeutic areas, CNS, inflammation and oncology," commented Michael C. Venuti, Ph.D., CEO of BioSeek.
"This collaboration leverages the power of our systems biology technology across multiple disease areas and multiple phases of the drug development process," said Venuti.
"The BioMAP® platform represents a very promising approach to applying the promise of whole-systems biology to the drug discovery and development process," stated Dr. Mark Bushfield, VP, NCE Research, UCB.
BioSeek's BioMAP® Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database.
BioMAP profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications.
In addition to characterizing previously identified lead compounds, BioSeek is using BioMAP Systems for primary screening, to generate lead compounds that have novel activity in a particular disease setting.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE